To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Infliximab (Primary)
- Indications Behcet's syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation
- 11 Jun 2016 Results presented at the 17th Annual Congress of the European League Against Rheumatism
- 03 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Apr 2014 New trial record